Cargando…

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mogollón, Pedro, Díaz-Tejedor, Andrea, Algarín, Esperanza M., Paíno, Teresa, Garayoa, Mercedes, Ocio, Enrique M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912619/ https://www.ncbi.nlm.nih.gov/pubmed/31766279 http://dx.doi.org/10.3390/cells8111432

Ejemplares similares

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression
por: Díaz-Tejedor, Andrea, et al.
Publicado: (2021)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA
por: Diaz-Tejedor, A., et al.
Publicado: (2022)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

The DAC system and associations with multiple myeloma
por: Ocio, Enrique M., et al.
Publicado: (2010)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
por: López-Iglesias, Ana-Alicia, et al.
Publicado: (2017)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Delforge, M., et al.
Publicado: (2022)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

Quark effects, meson exchange currents and background in the d(e,e'p)$\Delta$ reaction
por: Gómez-Tejedor, J A, et al.
Publicado: (1994)

Multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2020)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

Current and Emerging Treatments for Multiple Myeloma
por: Schwartz, Rowena N., et al.
Publicado: (2008)

The role of epigenetics in the biology of multiple myeloma
por: Dimopoulos, K, et al.
Publicado: (2014)

P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2-YEAR FOLLOW-UP
por: Moreau, Philippe, et al.
Publicado: (2023)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
por: Usmani, Saad Z, et al.
Publicado: (2023)

Biological Effective Radiation Dose for Multiple Myeloma Palliation
por: Meredith, Ruby F., et al.
Publicado: (2023)

Consolidation in multiple myeloma – current status and perspectives
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2014)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

Current and Future PET Imaging for Multiple Myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2023)

Biological determinants of health disparities in multiple myeloma
por: Smith, Cheryl Jacobs, et al.
Publicado: (2018)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
por: Ocio, Enrique M., et al.
Publicado: (2023)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Mateos, María Victoria, et al.
Publicado: (2022)

Proteomic profiling dataset of chemical perturbations in multiple biological backgrounds
por: Dele-Oni, Deborah O., et al.
Publicado: (2021)

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Usmani, S, et al.
Publicado: (2022)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
por: Abramson, Hanley N.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ean3nt6aflnea76p5ikii5nvt